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Hensin/DMBT1 deletion prevents 
conversion of β- to α-intercalated 
cells and induces distal renal 
tubular acidosis
Gao et al., Proc Natl Acad Sci USA 2010; 107: 21872–21877; doi:10.1073/
pnas.1010364107
Acid–base transport in the renal collecting tubule is mediated by 
the intercalated cells, which exist in two functionally distinct sub-
types. The α-cells secrete acid by an apical vacuolar H+-ATPase 
(V-ATPase) and a basolateral Cl:HCO3 exchanger, which is an 
alternately spliced form of the red-cell anion exchanger AE1. 
The β-type cells secrete HCO3− by an apical Cl:HCO3 exchanger 
called pendrin (Slc26a4) and a basolateral V-ATPase. In both cell 
types, the same or a very similar V-ATPase is located in the apical 
membrane of the α-form and in the basolateral membrane of the 
β-type. It was previously found that metabolic acidosis markedly 
reduced the number of β-intercalated cells, whereas it increased 
the number of α-intercalated cells, and because the total number 
of intercalated cells remained the same, these results were inter-
preted as indicating that the β-intercalated cell can convert to 
an α-phenotype. Additional work with a collecting duct cell line 
found that α-like intercalated cells deposited an extracellular 
matrix protein (termed hensin or DMBT1), which was by itself 
able to induce an α-intercalated-cell phenotype. As the global 
deletion of hensin resulted in early embryonic lethality, Gao et 
al. conditionally deleted its gene from only the intercalated cells 
or from all collecting duct cells to examine in vivo the role of 
hensin in the control of intercalated cells. In both instances, this 
resulted in an almost complete absence of typical α-intercalated 
cells (Figure). In addition, because, in vitro, integrin β1 was 
needed for polymerization and deposition of hensin, they also 
deleted integrin β1 in the intercalated cells; this also prevented 
the conversion of β- to α-intercalated cells. As expected, in all 
three instances, the presence of only HCO3-secreting β-cells 
produced complete distal renal tubular acidosis. These elegant 
results demonstrate that deletion of hensin leads to accumula-
tion of β-intercalated and lack of α-intercalated cells, indicating 
that there is a path of differentiation in which the β-cell is less 
differentiated than the α-type.
Juan Oliver
S-glutathionylation regulates 
eNOS function
Chen et al., Nature 2010; 468: 1115–1118; doi:10.1038/nature09599
Endothelial nitric oxide synthase (eNOS) is a critical enzyme regu-
lating vascular function, blood pressure, and kidney function. It 
can generate nitric oxide (NO) as well as superoxide (O2•−), both 
important mediators of cellular signaling. In the presence of Ca2+/
calmodulin, eNOS produces NO from l-arginine by means of elec-
tron transfer from NADPH to oxygen bound at the heme of an 
oxygenase domain, which also contains binding sites for tetrahy-
drobiopterin (BH4) and l-arginine. However, in the absence of 
BH4, NO synthesis is abrogated and, instead, O2•− is generated. 
NOS dysfunction occurs in diseases with redox stress, but BH4 
repletion only partly restores NOS activity, suggesting that an as-
yet unidentified redox-regulated mechanism controls NOS func-
tion. Protein thiols can undergo S-glutathionylation, a reversible 
protein modification involved in cellular signaling and adaptation. 
Under oxidative stress, S-glutathionylation can occur through 
thiol–disulphide exchange with oxidized glutathione or reaction 
of oxidant-induced protein thiyl radicals with reduced glutathione. 
Because cysteine residues are critical for eNOS function, Chen 
et al. postulated that oxidative stress could alter eNOS activity 
through S-glutathionylation. They found that S-glutathionylation 
of eNOS reversibly decreased NOS activity with an increase in O2•− 
generation. They identified two highly conserved cysteine residues 
 Immunofluorescence confocal images from the kidneys of wild-type 
(WT) and hensin-deleted mice. Note that in the hensin-deleted kidneys 
there was disappearance of the basolateral Cl:HCO3 exchanger that 
characterizes the α-intercalated cells but that the antibody to AE1 
stained the red blood cells remaining in the kidney vasculature.
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eNOS S-glutathionylation of aorta from spontaneously hypertensive 
rats (SHR) and normal rats (WKY). As shown, in SHR, eNOS 
S-glutathionylation was markedly increased in comparison with 
WKY rats, and this difference was abolished by pretreatment with 
dithiothreitol (DTT). Bottom: Ratio of relative intensity of eNOS 
S-glutathionylation/eNOS, normalized to SHR aortas. There was no 
detectable (n.d) eNOS S-glutathionylation in WKY aortas, whereas there 
were high levels in SHR. PrS-SG, protein S-glutathionylation.
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as the sites of S-glutathionylation and found them to be critical for 
redox regulation of eNOS function. They also found that eNOS 
S-glutathionylation in endothelial cells induced loss of NO and 
gain of O2•− generation and that this was associated with impaired 
endothelium-dependent vasodilation. Importantly, they found 
that hypertensive vessels (with impaired endothelium-dependent 
vasodilation) had increased eNOS S-glutathionylation (Figure) and 
that thiol-specific reducing agents restored their impaired endothe-
lium-dependent vasodilation and reversed the S-glutathionylation. 
Hence, the study shows that S-glutathionylation of eNOS is a piv-
otal switch providing redox regulation of endothelial cell signaling 
and vascular tone. These observations provide a new understand-
ing of how oxidant stress alters endothelial function and vascular 
tone and suggest that restoration or supplementation of reducing 
equivalents may restore endothelial function and normalize vas-
cular tone in hypertension and other vascular diseases.
Juan Oliver
The proteoglycan biglycan 
regulates expression of the B-cell 
chemoattractant CXCL13 and 
aggravates murine lupus nephritis
Moreth et al., J Clin Invest 2010; 120: 4251–4272; doi:10.1172/JCI42213
Chemokines and their receptors play an important role in the 
induction of autoimmune manifestations of systemic lupus ery-
thematosus (SLE) and in progressive lupus nephritis. Among the 
chemokines, CXCL13 is a key B-cell chemoattractant and marker 
of disease activity in patients with SLE. Therefore, Moreth et al. 
examined the mechanism of CXCL13 induction in SLE. They 
show that the proteoglycan biglycan, either secreted from cells or 
released from extracellular matrix, triggers CXCL13 expression 
via Toll-like receptor 2 (TLR2) and TLR4 in macrophages and 
dendritic cells. In vivo, levels of biglycan were markedly elevated 
in the plasma and kidneys of human SLE patients and lupus-
prone (MRL/lpr) mice. Overexpression of soluble biglycan in 
MRL/lpr mice raised CXCL13, caused accumulation of B cells 
in the kidney, and worsened organ damage, and albuminuria. 
Conversely, biglycan deficiency improved systemic and renal 
outcome in lupus mice, reducing autoantibodies, spleen and 
lymph node enlargement, renal damage, and albuminuria, and 
correlated with a decline in CXCL13 and in the number of B 
cells in the kidney. The authors postulate that biglycan, acting as 
an endogenous danger molecule, binds to TLR2 and TLR4 and 
thereby activates CXCL13.
This study further supports the role of endogenous danger mol-
ecules, such as biglycan, as activators of innate immune receptors 
and extends the concept from their being a major factor in the 
infiltrate of T cells, macrophages, and dendritic cells to B cells 
and their autoantibody production. These findings may also be 
of interest in view of the anti-B-cell-directed therapies introduced 
into the therapy of SLE.
Detlef Schlöndorff
Collaborative care for patients with 
depression and chronic illness
Katon et al., N Engl J Med 2010; 363: 2611–2620
Depression is increasingly recognized as being highly prevalent 
among patients with kidney disease and end-stage renal disease 
and significantly associated with bad outcomes as well. This 
clinical trial reports success in the treatment of depression in 
improving patient adherence and intermediate outcomes among 
patients with diabetes and heart disease. Investigators enrolled 
214 patients with poorly controlled diabetes, coronary heart dis-
ease, or both, and existing depression. Patients were randomized 
to a usual-care group or to the group receiving intervention. 
The 12-month intervention was designed to manage depres-
sion and improve glycemic, blood pressure, and lipid control by 
combining support for self-care with pharmacotherapy to con-
trol depression as well as the other medical problems. Patients 
worked collaboratively to establish individual clinical and self-
care goals in structured visits. Motivational coaching was used to 
assist patients in solving problems and setting goals for improved 
medication adherence and care. Research assistants blinded to 
treatment assignment conducted phone interviews at baseline, 6 
months, and 12 months to assess depression symptoms, health-
risk behaviors, and patient satisfaction. Also, intermediate mark-
ers of care such as blood pressure and glycated hemoglobin levels 
were measured at the same time points. At baseline, there were 
no differences between the group receiving intervention and the 
group receiving usual care. Patients were in their mid-50s with 
glycated hemoglobin levels of approximately 8% and body mass 
indices in the mid-30s. At 12 months, patients in the interven-
tion group experienced greater improvement with respect to 
glycated hemoglobin, LDL cholesterol, systolic blood pressure, 
and depressant outcomes. The intervention group on average saw 
an improvement of 0.81% in glycated hemoglobin, whereas the 
usual-care group saw an improvement of only 0.23%. The inter-
vention group achieved a statistically significant improvement 
of 15 mg/dl reduction in LDL cholesterol, whereas the usual-
care group achieved only an 8-mg/dl reduction. A trend toward 
decreasing systolic blood pressure did not reach conventional lev-
els of statistical significance. The mechanism for these improve-
ments may be through an increased number of adjustments in 
medications in the intervention group. Medication adherence 
was not assessed, and adherence to dietary and exercise recom-
mendations did not appear to be different between groups.
This study demonstrates that clinical benchmarks of care can 
be realized among patients with depression using this collabora-
tive care approach. Although these benefits appear modest, the 
subgroups that likely received greater benefit from this approach 
deserve further exploration. As we consider how to care for our 
patients with kidney disease with awareness of the impact of 
depression on quality of life as well as the ability of patients to 
partner with their physicians, these strategies may hopefully find 
their way into our practices.
Lynda Szczech
